Diabetes Research: Open Access

Diabetes Research: Open Access

Hiroshi Bando^1,2iD*
1Medical Research/Tokushima University, Tokushima, Japan
²Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan

Corresponding Author: Hiroshi Bando ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 30 September 2024; Accepted date: 26 October 2024; Published date: 02 November 2024

Citation: Bando H. Possible Adverse Effects (AEs) of Semaglutide (Ozempic) Administration for the Latest Investigation. Diab Res Open Access. 2024 Nov 02;5(1):17-20.

Copyright © 2024 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Semaglutide, Adverse Effects (AE), Ozempic Tongue, Tirzepatide, FDA Adverse Event Reporting System (FAERS)

Abstract

Semaglutide has been widely used in the treatment of type 2 diabetes (T2D) and obesity within medical and healthcare settings. Among its formulations, Ozempic has drawn attention for potential adverse effects (AEs). In a study involving 3,962 cases of obesity, the average data showed a weight reduction of 11.8%, a BMI decrease of 4.5 kg/m², and a reduction in waist circumference of 9.4 cm. One notable effect, termed “Ozempic tongue,” is characterized by altered taste sensitivity—such as sour, metallic, or bitter tastes—reported in approximately 6% of cases. These effects are not only considered AEs but are also linked to beneficial outcomes in weight reduction. Additionally, some users have reported changes in the appearance of the breasts, buttocks, and lips with Ozempic administration.